188 related articles for article (PubMed ID: 36380167)
1. Bone-Targeted Dual Functional Lipid-coated Drug Delivery System for Osteosarcoma Therapy.
Zhong J; Wen W; Wang J; Zhang M; Jia Y; Ma X; Su YX; Wang Y; Lan X
Pharm Res; 2023 Jan; 40(1):231-243. PubMed ID: 36380167
[TBL] [Abstract][Full Text] [Related]
2. Selenium-doped calcium carbonate nanoparticles loaded with cisplatin enhance efficiency and reduce side effects.
Zhao P; Li M; Chen Y; He C; Zhang X; Fan T; Yang T; Lu Y; Lee RJ; Ma X; Luo J; Xiang G
Int J Pharm; 2019 Oct; 570():118638. PubMed ID: 31449842
[TBL] [Abstract][Full Text] [Related]
3. Alendronate Pt
Sun K; Yuan L; Chen S; Sun Y; Wei D
Adv Healthc Mater; 2024 Mar; 13(7):e2302746. PubMed ID: 37988194
[TBL] [Abstract][Full Text] [Related]
4. Low molecular weight heparin modified bone targeting liposomes for orthotopic osteosarcoma and breast cancer bone metastatic tumors.
Wu H; Luo Y; Xu D; Ke X; Ci T
Int J Biol Macromol; 2020 Dec; 164():2583-2597. PubMed ID: 32795579
[TBL] [Abstract][Full Text] [Related]
5. [Lethal effects of nanoliposome encapsulated cisplatin on Saos-2 cells and its distribution in nude mice bearing human].
Wang GW; Guo W; Tang XD; Peng CL; Zhao H
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Oct; 41(5):525-30. PubMed ID: 19829667
[TBL] [Abstract][Full Text] [Related]
6. Engineered nanomedicine for myeloma and bone microenvironment targeting.
Swami A; Reagan MR; Basto P; Mishima Y; Kamaly N; Glavey S; Zhang S; Moschetta M; Seevaratnam D; Zhang Y; Liu J; Memarzadeh M; Wu J; Manier S; Shi J; Bertrand N; Lu ZN; Nagano K; Baron R; Sacco A; Roccaro AM; Farokhzad OC; Ghobrial IM
Proc Natl Acad Sci U S A; 2014 Jul; 111(28):10287-92. PubMed ID: 24982170
[TBL] [Abstract][Full Text] [Related]
7. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation.
Tseng CL; Su WY; Yen KC; Yang KC; Lin FH
Biomaterials; 2009 Jul; 30(20):3476-85. PubMed ID: 19345990
[TBL] [Abstract][Full Text] [Related]
8. Advanced nanoscale drug delivery systems for bone cancer therapy.
Amiryaghoubi N; Fathi M; Barar J; Omidian H; Omidi Y
Biochim Biophys Acta Mol Basis Dis; 2023 Aug; 1869(6):166739. PubMed ID: 37146918
[TBL] [Abstract][Full Text] [Related]
9. Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines.
Robson H; Meyer S; Shalet SM; Anderson E; Roberts S; Eden OB
Med Pediatr Oncol; 2002 Dec; 39(6):573-80. PubMed ID: 12376980
[TBL] [Abstract][Full Text] [Related]
10. In situ Co-Delivery of Doxorubicin and Cisplatin by Injectable Thermosensitive Hydrogels for Enhanced Osteosarcoma Treatment.
Si M; Xia Y; Cong M; Wang D; Hou Y; Ma H
Int J Nanomedicine; 2022; 17():1309-1322. PubMed ID: 35345787
[TBL] [Abstract][Full Text] [Related]
11. Advances in Bone-targeted Drug Delivery Systems for Neoadjuvant Chemotherapy for Osteosarcoma.
Li CJ; Liu XZ; Zhang L; Chen LB; Shi X; Wu SJ; Zhao JN
Orthop Surg; 2016 May; 8(2):105-10. PubMed ID: 27384718
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonate-functionalized coordination polymer nanoparticles for the treatment of bone metastatic breast cancer.
He Y; Huang Y; Huang Z; Jiang Y; Sun X; Shen Y; Chu W; Zhao C
J Control Release; 2017 Oct; 264():76-88. PubMed ID: 28842315
[TBL] [Abstract][Full Text] [Related]
13. Application of nanoparticles in drug delivery for the treatment of osteosarcoma: focussing on the liposomes.
Liang W; Dong Y; Shao R; Zhang S; Wu X; Huang X; Sun B; Zeng B; Zhao J
J Drug Target; 2022 Jun; 30(5):463-475. PubMed ID: 34962448
[TBL] [Abstract][Full Text] [Related]
14. Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy.
Li Y; Hou H; Zhang P; Zhang Z
Drug Deliv; 2020 Dec; 27(1):1044-1053. PubMed ID: 32633576
[TBL] [Abstract][Full Text] [Related]
15. EGFR-targeting peptide conjugated polymer-lipid hybrid nanoparticles for delivery of salinomycin to osteosarcoma.
Du L; Xu Y; Han B; Wang Y; Zeng Q; Shao M; Yu Z
J Cancer Res Ther; 2023 Dec; 19(6):1544-1551. PubMed ID: 38156920
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of the antitumor effect of calcium phosphate cement containing anticancer drug and caffeine on rat osteosarcoma.
Tanzawa Y; Tsuchiya H; Shirai T; Nishida H; Hayashi K; Takeuchi A; Kawahara M; Tomita K
J Orthop Sci; 2011 Jan; 16(1):77-84. PubMed ID: 21360005
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of intraarterial and intravenous cisplatin chemotherapy in the treatment of metastatic osteosarcoma using an orthotopic xenograft mouse model.
Robl B; Botter SM; Pellegrini G; Neklyudova O; Fuchs B
J Exp Clin Cancer Res; 2016 Jul; 35(1):113. PubMed ID: 27421768
[TBL] [Abstract][Full Text] [Related]
18. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
[TBL] [Abstract][Full Text] [Related]
19. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
[TBL] [Abstract][Full Text] [Related]
20. The antitumor effect of liposome-encapsulated cisplatin on rat osteosarcoma and its enhancement by caffeine.
Karita M; Tsuchiya H; Kawahara M; Kasaoka S; Tomita K
Anticancer Res; 2008; 28(3A):1449-57. PubMed ID: 18630498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
